Pulse Biosciences (NASDAQ:PLSE) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Pulse Biosciences (NASDAQ:PLSE) announced its earnings results on Thursday. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.06, FiscalAI reports.

Pulse Biosciences Stock Performance

Shares of NASDAQ:PLSE traded down $0.38 during mid-day trading on Thursday, hitting $25.08. 393,312 shares of the company traded hands, compared to its average volume of 360,437. The firm’s 50 day simple moving average is $15.98 and its 200 day simple moving average is $15.97. Pulse Biosciences has a 52-week low of $12.56 and a 52-week high of $26.30. The firm has a market cap of $1.70 billion, a P/E ratio of -22.19 and a beta of 1.77.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Mizuho set a $30.00 price target on Pulse Biosciences in a research note on Friday, February 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Pulse Biosciences currently has an average rating of “Hold” and an average target price of $26.00.

Insiders Place Their Bets

In related news, insider Kevin Patrick Danahy sold 20,000 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $23.63, for a total value of $472,600.00. Following the completion of the sale, the insider directly owned 43,298 shares of the company’s stock, valued at $1,023,131.74. The trade was a 31.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders sold 80,000 shares of company stock worth $1,876,200. 74.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Pulse Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of PLSE. Jane Street Group LLC purchased a new position in Pulse Biosciences in the first quarter valued at about $323,000. Creative Planning raised its position in Pulse Biosciences by 26.3% in the second quarter. Creative Planning now owns 18,971 shares of the company’s stock worth $286,000 after purchasing an additional 3,951 shares in the last quarter. Legal & General Group Plc lifted its holdings in Pulse Biosciences by 57.7% during the 2nd quarter. Legal & General Group Plc now owns 22,415 shares of the company’s stock valued at $338,000 after purchasing an additional 8,197 shares during the last quarter. Norges Bank bought a new stake in shares of Pulse Biosciences during the second quarter worth $302,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Pulse Biosciences during the second quarter valued at approximately $158,000. 76.95% of the stock is owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.